logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASH 2018 — Ibrutinib/rituximab tops FCR for PFS, OS in untreated CLL

Phase 3 E1912 study establishes new standard of care for younger patients.